Lunit Inc. (KOSDAQ:328130)
14,980
+590 (4.10%)
Oct 29, 2026, 3:30 PM KST
Lunit Revenue
Lunit had revenue of 21.81B KRW in the quarter ending June 30, 2026, with 22.04% growth. This brings the company's total for the last twelve months to 91.82B, up 24.27% year-over-year. In the year 2025, Lunit had annual revenue of 83.13B with 53.43% growth. That makes Lunit the 25,578th largest company in the world by revenue and 1,507th in South Korea.
Revenue (ttm)
91.82B
Revenue Growth
+24.27%
P/S Ratio
11.67
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.12T
Revenue by Geography
- Americas 56.63B 68.1%
- Asia Pacific 12.92B 15.5%
- Europe and Other 7.25B 8.7%
- South Korea 6.33B 7.6%
Fiscal year ended Dec 31, 2025 See the full Lunit breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 83.13B | 28.95B | 53.43% |
| Dec 31, 2024 | 54.18B | 29.10B | 116.03% |
| Dec 31, 2023 | 25.08B | 11.21B | 80.88% |
| Dec 31, 2022 | 13.87B | 7.23B | 108.85% |
| Dec 31, 2021 | 6.64B | 5.21B | 364.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Daewoong Pharmaceutical | 1.64T |
| Samsung Epis Holdings | 1.51T |
| DongKook Pharmaceutical | 979.60B |
| HK inno.N | 839.63B |
| ALTEOGEN | 254.01B |
| Sphere | 177.06B |